| CYTK |
Cytokinetics, Incorporated |
92%
|
Reciprocal relationship from CYTK graph: We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and CK-586 with affiliates of Royalty Pharma, … |
| DNLI |
Denali Therapeutics Inc. |
90%
|
Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: The information contained in Item 1.01 of the Form 8-K filed by Denali Thera… |
| SNDX |
Syndax Pharmaceuticals, Inc. |
90%
|
Reciprocal relationship from SNDX graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: the Purchase and Sale Agreement provides that if certain events of default o… |
| VERTEX |
VERTEX |
90%
|
Royalty payor that accounted for 36% of our total income and other revenues in 2024 and 2023 |
| ARWR |
Arrowhead Pharmaceuticals, Inc. |
85%
|
Reciprocal relationship from ARWR graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR g… |
| ROCHE |
ROCHE |
80%
|
Royalty payor that accounted for 10% of our total income and other revenues in 2024 |
| CYTK |
Cytokinetics, Incorporated |
72%
|
portion of the EPAs may be paid in cash as a tax advance to cover income tax obligations incurred by the beneficial owners of the RP Holdings Class C Special Interest. Mr. Legorreta granted ownership… |
| JNJ |
Johnson & Johnson |
72%
|
. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: . As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned … |
| NUVL |
Nuvalent, Inc. |
72%
|
Reciprocal relationship from NUVL graph: d other current assets of $16.9 million. During the year ended December 31, 2024, operating activities used $185.1 million of cash, resulting from our net los… |
| RVMD |
Revolution Medicines, Inc. |
72%
|
Reciprocal relationship from RVMD graph: Reciprocal relationship from RPRX graph: STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that… |
| RVMD |
Revolution Medicines, Inc. |
72%
|
STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RPRX graph: 1, 2024 and 2023 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are… |
| SNYNF |
Sanofi |
72%
|
1, 2024 and 2023 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 inputs. Our estimate of the risk adjusted discount rates could reasonably … |
| TBPH |
Theravance Biopharma, Inc. |
72%
|
. As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi… |
| TBPH |
Theravance Biopharma, Inc. |
72%
|
Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: . As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned… |
| APIJECT-HOLDINGS-INC |
APIJECT-HOLDINGS-INC |
62%
|
ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash … |
| CONTROLLED-FOREIGN-COMPANY |
CONTROLLED-FOREIGN-COMPANY |
62%
|
engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years pres… |
| FOLLOWING-PFIZER-INC |
FOLLOWING-PFIZER-INC |
62%
|
ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash … |
| INTERNALIZATION-RP-HOLDINGS |
INTERNALIZATION-RP-HOLDINGS |
62%
|
STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity … |
| LEGORRETA-INVESTMENTS-II-LLC |
LEGORRETA-INVESTMENTS-II-LLC |
62%
|
STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity … |
| MA |
Mastercard Incorporated |
62%
|
Reciprocal relationship from MA graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from MA graph: Reciprocal relationship from RPRX graph: MA PLC NOTES TO THE CONDENSED CONSOLIDA… |
| MA-PLC |
MA-PLC |
62%
|
MA PLC NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Legal Proceedings We are a party to legal actions with respect to a variety of matters in the ordinary course of business. … |
| PABLO-LEGORRETA-LEGORRETA-INVESTMENTS-LLC |
PABLO-LEGORRETA-LEGORRETA-INVESTMENTS-LLC |
62%
|
STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity … |
| PABLO-LEGORRETA-RPM-I-LLC |
PABLO-LEGORRETA-RPM-I-LLC |
62%
|
MA PLC NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Legal Proceedings We are a party to legal actions with respect to a variety of matters in the ordinary course of business. … |
| ROYALTY-PHARMA-LLC |
ROYALTY-PHARMA-LLC |
62%
|
pts for all new portfolio investments in a Portfolio less Total Expenses, which is defined as interest expense, operating expense and recovery of acquisition cost related to that Portfolio. Distribut… |
| RP-HOLDINGS |
RP-HOLDINGS |
62%
|
idated affiliates: 1. Legacy SLP Interest. In connection with the Exchange Offer, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited p… |
| RP-MIP-HOLDINGS |
RP-MIP-HOLDINGS |
62%
|
MA PLC NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Legal Proceedings We are a party to legal actions with respect to a variety of matters in the ordinary course of business. … |
| RP-MIP-HOLDINGS-LLC |
RP-MIP-HOLDINGS-LLC |
62%
|
terial changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025. 3. Internalization On January 10, 2025, we entered into an agreement (a… |
| RPM-ROYALTY-PHARMA-MANAGER-LLC |
RPM-ROYALTY-PHARMA-MANAGER-LLC |
62%
|
terial changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025. 3. Internalization On January 10, 2025, we entered into an agreement (a… |
